Genderinfo.nl
News

MTF

Box and blister pack of Progynova tablets (estradiol valerate)
Photo: Asatsuyu2022, CC BY-SA 4.0, via Wikimedia Commons

'MTF' stands for 'male-to-female' and describes a person assigned male at birth who has undergone or is undergoing a transition in a female direction. The abbreviation originates from English-language medical literature and has been commonly used for decades by gender clinics and self-advocacy organizations.

What does it mean?

MTF is generally used for people undergoing a full social and/or medical transition: from male to female pronouns, clothing, social role and—in the case of medical transition—estrogen, sometimes supplemented by vaginoplasty and facial surgery (FFS). Orchiectomy, breast augmentation and voice training may also form part of the process.

Distinctions and overlap

MTF and transfeminine overlap, but are not identical. MTF generally implies a 'full transition to womanhood' and, in that context, is older, established medical terminology. Transfeminine is more recent and broader, and also includes non-binary AMAB pathways. 'Transgender woman' is common in public language; MTF is sometimes perceived as 'clinical' or 'old-fashioned', and some activist circles prefer to avoid the term.

Social and practical context

The abbreviation MTF still appears on forms, in medical records and in research. For MTF individuals, medical pathways involve the usual considerations regarding hormone side effects, fertility (with the option of sperm cryopreservation), and the nature of surgical procedures.

Critical perspectives

Medical transition from AMAB to a female presentation does not produce a biologically female body. For most social purposes, this is not an issue; in specific contexts (sports, medical screening and some legal matters), sex assigned at birth remains relevant. A fair assessment of the benefits and drawbacks—including lifelong medication and the consequences of surgery—is essential in any MTF consideration. With long-term estrogen use, this includes the risk of thrombosis and the risk of cardiovascular disease; an overview with sources is available at transwijzer.nl.

Sources

  • Hembree, W.C. et al. (2017). "Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons." JCEM, 102(11). DOI
  • Coleman, E. et al. (2022). WPATH Standards of Care, Version 8. DOI
  • Benjamin, Harry (1966). The Transsexual Phenomenon. Julian Press. (klassieke MTF-terminologie)
  • Dhejne, C. et al. (2011). "Long-term follow-up of transsexual persons undergoing sex reassignment surgery." PLOS ONE, 6(2). PubMed
  • van Heesewijk, J. et al. (2024). "Long-term gender-affirming hormone therapy and cognitive functioning in older transgender women." Nederlandse studie.